alt Hacker Newsnot really a huge win. It's going to cost taxpayers significancy and may not improve survival much or total life expectancy . The stock is way overextended, assuming it even works well enough to be a commercial success. History has shown this is seldom the case. I would short it if wasn't so expensive and risky to do so. They would not even specify how much it improved the 5 year survival rate.
> not really a huge win. It's going to cost taxpayers significancy and may not improve survival much or total life expectancy . The stock is way overextended. It's a long way from anything that can be used on patients, assuming it even works well enough to be a commercial success. History has shown this is seldom the case. I would short it if wasn't so expensive and risky to do so.
Buddy, this is a phase 3 trial. This is about as close as you can get to "anything that can be used on patients" without already being approved.
It is clear that you don't have experience in this area.